View Cancer Clinical Trials
A Study of Outcomes and Toxicity of Busulfex as Part of a High Dose Chemotherapy Preparative Regimen in Autologous Hematopoietic Stem Cell Transplantation for Patients with Plasma Cell Myeloma
|Blood & Marrow Transplant (BMT)
- Primary Objective:
- To compare relapse-free survival and overall survival between Busulfex and oral Busulfan when used for conditioning with cyclophosphamide in plasma cell myeloma patients undergoing autologous HSCT.
- Secondary Objectives:
- To compare pulmonary toxicity rates between Busulfex and oral Busulfan when used for conditioning with cyclophosphamide in plasma cell myeloma patients undergoing autologous HSCT.
- Patients with a diagnosis of plasma cell myeloma
- Patients with cardiac ejection fraction ≥ 45% or clearance by CCF cardiologist
- Patients with DLCO ≥ 45% predicted or clearance by CCF pulmonologist
- Patient with previously harvested peripheral blood progenitor cells with a minimum of 2 x 10^6 CD34+ cells/kg harvested
- Patient is greater than 18 years of age
- Patients receiving total body irradiation
- Non-myeloablative/reduced-intensity conditioning
- Pregnant or breast-feeding patients
- HIV positive
- Patient with Serum creatinine > 2.0
- Prior HSC transplant
Cancer Answers & Appointments
Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.
Monday through Friday from 8 a.m. – 4:30 p.m. (ET).
Resources for medical professionals
- Outpatient appointment referrals: 216.444.7923 or 866.223.8100
- Inpatient hospital transfers: 800.553.5056
- Referring Physician Concierge: 216.444.6196 or 216.312.4910.
Search available cancer clinical trials by disease, hospital, phase or number.
This information is provided by Cleveland Clinic and is not intended to replace
the medical advice of your doctor or health care provider.
Please consult your health care provider for advice about a specific medical condition.
© Copyright 2016 Cleveland Clinic. All rights reserved.